Fluticasone/Formoterol Combination Therapy Compared With Monotherapy in Adolescent and Adult Patients With Mild to Moderate Asthma

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages 950-966

  Pearlman, David S ^a   LaForce, Craig F ^b   Kaiser, Kirsten ^c  

^a Respiratory Institute   (United States)

^b North Carolina Clinical Research Inc   (United States)

^c SkyePharma   (Switzerland)

Author keywords

Asthma; Combination therapy; Fluticasone; Formoterol; Inhaled corticosteroid; Long acting 2 agonist

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CONNECTIVE TISSUE DISEASE; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; GROUPS BY AGE; HAY FEVER; HEADACHE; HUMAN; INFECTION; INFESTATION; LABORATORY TEST; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METERED DOSE INHALER; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCHOOL CHILD; SINUSITIS; SKIN DISEASE; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VITAL SIGN;

ASTHMA; COMBINATION THERAPY; FLUTICASONE; FORMOTEROL; INHALED CORTICOSTEROID; LONG-ACTING Β(2)-AGONIST;

ADOLESCENT; ADULT; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE;

EID: 84880445579     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.012     Document Type: Article

References (42)

1. GINA Report, Global Strategy for Asthma Management and Prevention. Accessed January 16, 2011. http://www.ginasthma.org/.
2. Murphy D.M., O'Byrne P.M. Recent advances in the pathophysiology of asthma. Chest 2010, 137:1417-1426.
3. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma, a report for the Global Initiative for Asthma. Accessed January 16, 2011. http://www.ginasthma.org.
4. Kupczyk M., Haahtela T., Cruz A.A., Kuna P. Reduction of asthma burden is possible through national asthma plans. Allergy 2010, 65:415-419.
5. Van Noord J.A., Schreurs A.J.M., Mol S.J.M., Mulder P.G.H. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999, 54:207-212.
6. Pauwels R.A., Lofdahl C.L., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997, 337:1405-1411.
7. Ward C., Pais M., Bish R., et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002, 57:309-316.
8. Stoloff S.W., Stempel D.A., Meyer J., et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004, 113:245-251.
9. Greening A.P., Ind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994, 344:219-224.
10. Woolcock A., Lundback B., Ringdal N., Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996, 153:1481-1488.
11. Naedele-Risha R., Dorinsky P., Craig T.J. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids. J Am Osteopathic Assoc 2001, 101:526-533.
12. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001, 164:1392-1397.
13. Thomas M., von Ziegenweidt J., Lee A.J., et al. High-dose inhaled corticosteroids versus add-on long-acting β-agonists in asthma: An observational study. Journal of Allergy and Clinical Immunology 2009, 123:116-121.
14. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. National Asthma Education and Prevention Program; National Institute of Health; National Heart, Lung, and Blood Institute. 2007, publication No.97-4051.
15. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2010, Issue 5. Art. No.: CD005535. DOI:10.1002/14651858.CD005535.pub2.
16. 2-agonists and corticosteroids. European Respiratory Journal 2002, 19:182-191.
17. Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595.
18. Marceau C., Lemiere C., Berbiche D., et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006, 118:574-581.
19. Delea T.E., Stanford R.H., Hagiwara M., Stempel D.A. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin 2008, 24:3435-3442.
20. Bateman E.D., Britton M., Carrillo J., et al. Salmeterol/fluticasone combination inhaler. Clin Drug Invest 1998, 16:193-201.
21. Kavuru M., Melamed J., Gross G., et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000, 105:1108-1116.
22. Stallberg B., Olsson P., Jorgensen L.A., et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003, 57:656-661.
23. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved?. Am J Respir Crit Care Med 2004, 170:836-844.
24. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
25. Huchon G., Magnussen H., Chuchalin A., et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49.
26. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13.
27. Accordini S., Bugiani M., Arossa W., et al. Poor control increases the economic cost of asthma. Int Arch Allergy Immunol 2006, 141:189-198.
28. Cazzoletti L., Marcon A., Janson C., et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007, 120:1360-1367.
29. Demoly P., Paggiaro P., Plaza V., et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev 2009, 18:105-112.
30. Virchow J.C., Crompton G.K., Dal Negro R., et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008, 102:10-19.
31. Adams N.P., Bestall J.C., Lasserson T.J., et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008, Issue 4. Art no: CD003135.
32. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines 2007, National Heart, Lung, and Blood Institute.
33. Ketchell R.I., Jensen M.W., Spina D., O'Connor B.J. Dose-related effects of formoterol on airway hyperresponsiveness to adenosine 5'-monophosphate and histamine. Eur Respir J 2002, 19:611-616.
34. Luijk B., Kempsford R.D., Wright A.M., et al. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004, 23:559-564.
35. Adams N.P., Bestall J.C., Jones P., et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008, Issue 4. Art no: CD003534.
36. Palmqvist M., Arvidsson P., Beckman O., et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001, 14:29-34.
37. Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999, 13:988-992.
38. Berger W.E. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006, 97:24-33.
39. Lotvall J., Ankerst J. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med 2008, 102:449-456.
40. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
41. Polgar G., Promdhat V. Pulmonary Function Testing in Children: Techniques and Standards 1971, WB Saunders, Philadelphia, Pa.
42. Crapo R.O., Morris A.H., Gardner R.M. Reference spirometric values using techniques and equipment that meets ATS recommendations. Am Rev Respir Dis 1981, 123:659-664.